The Clinical Effect of Remimazolam Tosilate for Injection Combined with Sufentanil in patients with Cirrhosis Undergoing Painless Gastroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042179

Enrollment

Unknown

Registered

2021-01-15

Start date

2021-02-28

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Gastroscopy

Interventions

experimental group:Given sufentanil 0.15 µ g / kg and Remimazolam Tosilate xxmg

control group:Given sufentanil 0.15ug/kg and propofol 1.5-2.0ug/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients with cirrhosis due to various etiologies; 2.ASA class II-III; 3.Aged 18-65 years; 4.Liver function child Pugh class A; 5.Indications for painless gastroscopy; 6.Agreed to be seen and treated with a sedated or anaesthetic gastroscope and to sign an informed consent form from the patient.

Exclusion criteria

Exclusion criteria: 1. Allergic to sedative, narcotic components. 2. Unable to take questionnaires due to various reasons.

Design outcomes

Primary

Measure	Time frame
Physician satisfaction with gastroscopy;Degree of respiratory depression SpO2;MoaA / s score at drug onset, end of operation;Perioperative limb movements;Need for additional dosing;Time of onset of sedation / anesthesia, time of gastroscopic manipulation, time of recovery of consciousness.;Vital signs: SBP, DBP, HR, RR;Adverse effects;Postoperative subjective questionnaire of patients;Digital connectivity trial a (NCT-A) completion time;	—

Measure

Time frame

Physician satisfaction with gastroscopy;Degree of respiratory depression SpO2;MoaA / s score at drug onset, end of operation;Perioperative limb movements;Need for additional dosing;Time of onset of sedation / anesthesia, time of gastroscopic manipulation, time of recovery of consciousness.;Vital signs: SBP, DBP, HR, RR;Adverse effects;Postoperative subjective questionnaire of patients;Digital connectivity trial a (NCT-A) completion time;

—

Countries

China

Contacts

Public ContactYinghao Cao

Bejing You'an Hospital Affiliated to Capital Medical University

cyhbj@sina.cn+86 13601091691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026